Mylan Voluntary Globally Recalls 2 Lots of Levoleucovorin (250mg/25ml) Injection Used to Prevent Harmful Effects of Methotrexate
- Mylan has recalled two lots of Levoleucovorin (250mg/25ml) injection to the consumer level having a lot number APB032 & APB033 due to presence of foreign particle as copper salt discovered during a 12-month stability testing
- The voluntary recall is done for the lots of Levoleucovorin- distributed between August 2017 to July 2018 in the US and is conducted within the knowledge of the US FDA
- Levoleucovorin (250mg/25ml) is a single-use vial antidote for dihydrofolate reductase by methotrexate and used as a combination therapy with 5-fluorouracil for advanced metastatic colorectal cancer- developed by Alidac Pharmaceuticals
Ref: Mylan | Image: Daily Post India
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].